Milestone Scientific (NYSE:MLSS) Research Coverage Started at Benchmark

Benchmark began coverage on shares of Milestone Scientific (NYSE:MLSS) in a report published on Thursday morning, MarketBeat Ratings reports. The brokerage issued a speculative buy rating and a $1.25 price target on the stock.

Separately, StockNews.com started coverage on Milestone Scientific in a report on Wednesday. They set a hold rating on the stock.

Milestone Scientific Price Performance

Shares of Milestone Scientific stock opened at $0.87 on Thursday. The firm has a fifty day moving average price of $0.96 and a two-hundred day moving average price of $0.80. Milestone Scientific has a fifty-two week low of $0.52 and a fifty-two week high of $1.10. The company has a market cap of $67.19 million, a PE ratio of -8.70 and a beta of 1.08.

Milestone Scientific (NYSE:MLSS) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The firm had revenue of $1.85 million for the quarter. Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%.

Insider Buying and Selling at Milestone Scientific

In other news, Director Leonard Osser sold 141,913 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $0.95, for a total value of $134,817.35. Following the sale, the director now owns 4,602,506 shares of the company’s stock, valued at approximately $4,372,380.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 143,122 shares of company stock valued at $136,026. 24.75% of the stock is currently owned by company insiders.

About Milestone Scientific

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.